Liquid Embolic Agent Market Size & Growth Forecast 2027–2036, By Segments (Application, End Use, Product Type), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Jump to Content
Market Size and Growth Outlook
Liquid Embolic Agent Market size stood at USD 302.66 million in 2026 and is predicted to grow at a 10.39% CAGR from 2027 to 2036, attaining USD 813.3 million by 2036. The industry revenue for 2027 is calculated at USD 329.35 million.
Get more details on this report
Request Free Sample ReportLiquid Embolic Agent Market Intelligence Snapshot
Regional Market Dynamics
- North America held 41.33% of the market, supported by advanced interventional radiology, specialized neurovascular centers, experienced clinicians, and growing adoption of minimally invasive treatments for complex vascular conditions.
- Asia Pacific is expected to grow fastest as healthcare modernization, specialized treatment center expansion, improved diagnostic imaging access, and increasing adoption of minimally invasive neurovascular procedures support broader use of liquid embolic agents.
Segment Momentum
- Arteriovenous malformations accounted for 49.49% of the market in 2026, supported by the use of liquid embolic agents for targeted vessel occlusion, complex vascular lesion management, and minimally invasive endovascular procedures.
- EVOH is the leading and fastest-growing product type, supported by its suitability for controlled embolization, effective vessel occlusion, and precise delivery during complex endovascular interventions, alongside improvements in formulations and delivery techniques.
Market Expansion Drivers
- Increasing prevalence of cerebrovascular disorders and aneurysms.
- Advancements in liquid embolic agent materials and delivery systems.
- Expansion of neurointerventional procedures in emerging markets.
Leading Market Participants
- Major players in the liquid embolic agent market include Medtronic (USA), Johnson & Johnson / Cerenovus (USA), Terumo Neuro (Japan), Balt (France), Boston Scientific (USA), Merit Medical Systems (USA), Arsenal Medical (USA), Meril Life Sciences (India), INVAMED (USA), Stryker (USA).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 302.66 million
- 2027 Estimated Market Size: USD 329.35 million
- Projected Market Size: USD 813.3 million by 2036
- Growth Forecast: 10.39% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Application (Arteriovenous Malformations (AVM)) | End Use (Hospitals) | Product Type (Ethylene Vinyl Alcohol Copolymer (EVOH))
- Emerging Opportunity Segment: Application (Arteriovenous Malformations (AVM)) | End Use (Hospitals) | Product Type (Ethylene Vinyl Alcohol Copolymer (EVOH))
Market Growth Drivers and Industry Trends
Increasing Prevalence of Cerebrovascular Disorders and Aneurysms
Increasing prevalence of cerebrovascular disorders and aneurysms is driving demand for liquid embolic agents as neurointerventional specialists increasingly utilize minimally invasive approaches for selected vascular conditions. These agents enable targeted embolization of abnormal blood vessels and can support treatment strategies designed to reduce blood flow to aneurysms or vascular malformations. Growing recognition of the clinical burden associated with cerebrovascular disease, combined with improvements in diagnosis and referral to specialized neurovascular centers, is expanding the pool of patients considered for endovascular intervention.
Advancements in Liquid Embolic Agent Materials and Delivery Systems
Advancements in liquid embolic agent materials and delivery systems are supporting market growth by improving control, precision, and procedural versatility during endovascular interventions. Innovations in polymer chemistry, radiopacity, viscosity, and solidification characteristics are enabling clinicians to tailor embolization approaches to complex vascular anatomies and different treatment requirements. Improvements in catheter and delivery technologies are further enhancing procedural navigation and agent deployment, encouraging broader adoption of liquid embolization techniques within specialized neurointerventional practice.
Expansion of Neurointerventional Procedures in Emerging Markets
Expansion of neurointerventional procedures in emerging markets is increasing demand for liquid embolic agents as specialized hospitals develop greater capacity for minimally invasive treatment of cerebrovascular conditions. Investments in advanced imaging infrastructure, catheterization facilities, specialist training, and multidisciplinary stroke care are improving access to endovascular procedures outside established healthcare centers. Growing awareness of minimally invasive treatment options and the gradual development of dedicated neurovascular services are further supporting the adoption of liquid embolization technologies in these developing healthcare systems.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Increasing prevalence of cerebrovascular disorders and aneurysms | 3% | Short term (≤ 2 yrs) | North America; Europe | Medium | Fast |
| Advancements in liquid embolic agent materials and delivery systems | 4% | Medium term (2–5 yrs) | North America; Asia Pacific | Medium | Moderate |
| Expansion of neurointerventional procedures in emerging markets | 3.5% | Long term (5+ yrs) | Asia Pacific; Latin America | Low | Moderate |
Explore Growth Opportunities
Request Free Sample ReportRegional Demand Dynamics
North America (Largest Region)
North America dominated the liquid embolic agent market, accounting for 41.33% share. The region’s leading position is supported by advanced healthcare infrastructure, established interventional radiology capabilities, and the growing adoption of minimally invasive procedures for treating complex vascular conditions. The availability of specialized neurovascular treatment centers, experienced clinicians, and advanced medical imaging technologies supports the use of liquid embolic agents in procedures involving arteriovenous malformations, aneurysms, and other vascular abnormalities. In addition, the emphasis on improving treatment precision, reducing procedural complications, and enhancing patient recovery is strengthening demand for advanced embolization solutions. Established clinical expertise and the integration of sophisticated catheter-based techniques into specialized care are further reinforcing regional market development. The presence of well-developed diagnostic and treatment pathways also supports the evaluation and adoption of innovative embolic materials, sustaining North America’s prominent position in the market.
Asia Pacific (Fastest-Growing Region)
Asia Pacific is expected to witness the fastest growth in the liquid embolic agent market, driven by improving healthcare infrastructure, increasing access to specialized neurovascular treatments, and the expanding adoption of minimally invasive medical procedures. Growing awareness of advanced treatment options for vascular disorders is encouraging healthcare providers to strengthen their interventional radiology and neurosurgical capabilities. Investments in modern medical facilities, improved access to diagnostic imaging, and the gradual expansion of specialized treatment centers are creating favorable conditions for the adoption of liquid embolic agents. Furthermore, rising demand for targeted treatments that can reduce the need for more invasive surgical interventions is supporting the development of regional embolization services. Improvements in clinician training and the broader availability of advanced catheter-based procedures are also contributing to market expansion, while continued healthcare modernization is expected to support wider access to specialized vascular care across the region.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation HubiScaleNascentDeveloping Advanced | |||||
| Cost-Sensitive RegioniScaleLowMedium High | |||||
| Regulatory EnvironmentiScaleRestrictiveNeutral Supportive | |||||
| Demand DriversiScaleWeakModerate Strong | |||||
| Development StageiScaleEmergingDeveloping Developed | |||||
| Adoption RateiScaleLowMedium High | |||||
| New Entrants / StartupsiScaleSparseModerate Dense | |||||
| Macro IndicatorsiScaleWeakStable Strong |
Key Country Insights
United States 🇺🇸
Advanced Neurovascular InterventionIn the U.S., liquid embolic agent priorities center on expanding minimally invasive treatment options for complex neurovascular and peripheral vascular conditions. Hospitals and specialists are likely to emphasize delivery-system compatibility, procedural precision, safety, and integration with increasingly specialized interventional workflows.
Germany 🇩🇪
Specialized Embolization PracticeGermany’s liquid embolic agent market is shaped by established interventional radiology and neurovascular capabilities, with attention to controlled embolization and procedural safety. Adoption priorities include physician training, consistent product performance, and integration into multidisciplinary pathways for complex vascular interventions.
Japan 🇯🇵
Precision Endovascular TherapyJapan’s market priorities emphasize precise delivery and controlled embolization within advanced endovascular procedures. Clinicians are likely to value predictable handling, catheter compatibility, and procedural efficiency, particularly as specialized centers refine minimally invasive approaches for challenging vascular lesions.
South Korea 🇰🇷
High-Skill Embolization ApplicationsSouth Korea’s liquid embolic agent market is supported by sophisticated interventional capabilities and demand for precise minimally invasive procedures. Commercial priorities include reliable delivery characteristics, operator familiarity, and products that facilitate controlled treatment of complex neurovascular and other vascular lesions.
France 🇫🇷
Multidisciplinary Vascular CareFrance’s liquid embolic agent priorities are closely connected to multidisciplinary management of complex vascular conditions. Hospitals and interventional teams are likely to focus on procedural precision, appropriate patient selection, product reliability, and coordination between radiology, neurology, and surgical services.
Italy 🇮🇹
Interventional Access DevelopmentItaly’s liquid embolic agent market places emphasis on expanding practical access to specialized embolization procedures. Key priorities include reliable catheter-based delivery, physician expertise, procedural efficiency, and integration of embolic technologies into established interventional radiology and vascular-care pathways.
Liquid Embolic Agent Market Share (%), by Application, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportApplication Segment Analysis: Arteriovenous Malformations (AVM) (Largest & Fastest-Growing Segment)
The arteriovenous malformations (AVM) segment accounted for the largest market share of 49.49% in 2026 and is also expected to grow at the fastest pace, supported by the increasing use of minimally invasive approaches for managing complex vascular abnormalities. Liquid embolic agents play an important role in endovascular procedures by enabling targeted occlusion of abnormal blood vessels and supporting the management of intricate vascular lesions. Their ability to conform to irregular vascular structures and facilitate controlled embolization makes them valuable in procedures where precise vessel treatment is required. Growing awareness of endovascular treatment options, advances in interventional techniques, and improvements in catheter-based delivery are contributing to broader adoption in AVM management. Continued development of embolic technologies aimed at improving procedural control, delivery characteristics, and treatment precision is expected to further support the role of AVM applications in the liquid embolic agent market throughout 2026.
End Use Segment Analysis: Hospitals (Largest & Fastest-Growing Segment)
The hospitals segment accounted for the largest 2026 market share of 50.64% and is also anticipated to register the fastest growth, reflecting the central role of hospitals in diagnosing and treating complex vascular conditions through specialized interventional procedures. Hospitals provide access to advanced imaging systems, interventional facilities, specialized clinicians, and multidisciplinary care teams required for procedures involving liquid embolic agents. The increasing adoption of minimally invasive vascular interventions is strengthening demand for specialized embolization products in hospital-based treatment settings. In addition, improvements in interventional radiology infrastructure and the growing availability of sophisticated catheter-based procedures are enabling hospitals to manage a broader range of vascular disorders. As healthcare systems continue to expand advanced procedural capabilities and emphasize less invasive treatment approaches, hospitals are expected to remain a key end-use setting for liquid embolic agents in 2026.
Product Type Segment Analysis: Ethylene Vinyl Alcohol Copolymer (EVOH) (Largest & Fastest-Growing Segment)
The ethylene vinyl alcohol copolymer (EVOH) segment holds the leading market share position in 2026 and is also expected to experience the fastest growth, supported by its favorable properties for controlled embolization procedures. EVOH-based liquid embolic agents can provide effective vessel occlusion while allowing clinicians to manage the delivery of the embolic material during complex endovascular interventions. Their established application in procedures requiring precise and durable embolization contributes to their strong adoption among interventional specialists. Ongoing advances in formulation characteristics and delivery techniques are further supporting the clinical utility of EVOH-based products, particularly where controlled penetration and predictable embolization are important. Increasing use of minimally invasive vascular procedures, together with growing demand for technologies that provide greater procedural precision, is expected to reinforce the adoption of EVOH in the liquid embolic agent market during 2026.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Application | Arteriovenous Malformations (AVM), Hypervascular Tumors, Peripheral Vasculature Hemorrhage, Others | Arteriovenous Malformations (AVM) | Arteriovenous Malformations (AVM) |
| End Use | Hospitals, Specialty Clinics, Ambulatory Surgical Centers (ASCs), Others | Hospitals | Hospitals |
| Product Type | Ethylene Vinyl Alcohol Copolymer (EVOH), Cyanoacrylates, Others | Ethylene Vinyl Alcohol Copolymer (EVOH) | Ethylene Vinyl Alcohol Copolymer (EVOH) |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Competitive Landscape and Market Positioning
Analyst Perspective:
Clinical success in the liquid embolic agent market relies on precise fluoroscopic visualization, controlled polymerization timing, and seamless catheter compatibility to ensure predictable delivery without unwanted material adherence. Because procedural outcomes and tissue responses vary by formulation and application, competitive strength is driven by robust safety evidence and consistent biocompatibility profiles rather than laboratory metrics alone.
Key companies in the liquid embolic agent market:
- Medtronic (USA)
- Johnson & Johnson / Cerenovus (USA)
- Terumo Neuro (Japan)
- Balt (France)
- Boston Scientific (USA)
- Merit Medical Systems (USA)
- Arsenal Medical (USA)
- Meril Life Sciences (India)
- INVAMED (USA)
- Stryker (USA)
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Medtronic (USA) | |||||||
| Johnson & Johnson / Cerenovus (USA) | |||||||
| Terumo Neuro (Japan) | |||||||
| Balt (France) | |||||||
| Boston Scientific (USA) | |||||||
| Merit Medical Systems (USA) | |||||||
| Arsenal Medical (USA) | |||||||
| Meril Life Sciences (India) | |||||||
| INVAMED (USA) | |||||||
| Stryker (USA) |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Balt | February 2026 | Balt received U.S. Food and Drug Administration (FDA) Premarket Approval (PMA) for its Squid liquid embolic agent. This regulatory milestone expands the availability of Balt's neurovascular technology in the U.S. market, establishing a new treatment option for middle meningeal artery embolization in patients with chronic subdural hematomas. |
| Medtronic | July 2025 | Medtronic announced the enrollment of the first patient in the Peripheral Onyx Liquid Embolic clinical trial. The study evaluates the safety and efficacy of the Onyx Liquid Embolic System for targeted embolization of arterial hemorrhages within the peripheral vasculature. |
| Balt | June 2025 | Balt completed the acquisition of its Canadian distributor, Yocan Medical Systems Ltd., which operates subsequently under the name Balt Canada Ltd. This direct operational presence establishes a new expansion milestone for the company's footprint in Canada. |
| Guerbet | February 2025 | Guerbet secured Breakthrough Device designation from the U.S. Food and Drug Administration for LIPIOJOINT, a transient liquid embolic agent designed to reduce pain and enhance mobility for patients diagnosed with knee osteoarthritis. |
| Arsenal Medical | July 2024 | Arsenal Medical reported that the open-label, multicenter prospective EMBO-01 clinical trial of NeoCast successfully met its primary safety and feasibility goals. The study validated the material's capability for predictable vascular occlusion and deep distal penetration into the microvasculature. |
| Johnson & Johnson | March 2024 | CERENOVUS, a division of Johnson & Johnson MedTech, launched the TRUFILL n-BCA Liquid Embolic System Procedural Set. The configuration integrates necessary accessories into a single sterilized package to streamline procedure preparation and expand the hemorrhagic stroke portfolio. |
| Sirtex Medical | October 2023 | Sirtex Medical initiated the commercial launch of the LAVA Liquid Embolic System, positioning it as a dedicated liquid embolic agent cleared for treating peripheral vascular hemorrhage. |
| China Grand Pharmaceutical and Healthcare Holdings Limited | May 2021 | China Grand Pharmaceutical and Healthcare Holdings Limited entered into an agreement to acquire a 100 percent equity interest in Jiangsu Shenming Medical Technology Co., Ltd. for USD 3.15 million. The transaction secures rights to develop and commercialize thermosensitive embolic agents indicated for liver cancer treatment. |
| Sirtex Medical | April 2021 | Sirtex Medical and BlackSwan Vascular enrolled their first patient in the pivotal LAVA Study across multiple investigational sites in the United States, successfully treating a bleeding hypervascular liver tumor using the Lava Liquid Embolic System. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Liquid Embolic Agent Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Embolization Technique | Transarterial Embolization, Transvenous Embolization, Direct Percutaneous Embolization |
| Target Vessel Size | Small Vessels, Medium Vessels, Large Vessels |
| Reimbursement Type | Public/Government Reimbursement, Private Insurance, Self-Pay/Out-of-Pocket |
Liquid Embolic Agent Market — Custom TOC
| Custom Chapter | Chapter Details |
|---|---|
| Interventional Procedure Adoption Pathways |
|
| Clinical Indication Expansion Opportunities |
|
| Embolization Center Market Access Analysis |
|
Need a different cut of the data?
Request Custom ResearchFrequently Asked Questions
How large is the liquid embolic agent market?
What is the projected value of the liquid embolic agent industry by 2036?
How are advances in embolic materials and delivery systems expanding clinical adoption?
How is neurointerventional infrastructure expansion supporting demand for liquid embolic agents?
Why do arteriovenous malformations lead demand in the liquid embolic agent market?
How are EVOH-based products strengthening their position in the liquid embolic agent market?
Why does North America dominate the liquid embolic agent market?
How is Asia Pacific creating growth opportunities in the liquid embolic agent market?
Which companies are driving growth in the liquid embolic agent landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
This report was prepared by the Healthcare & Medical Devices Research Team at Fundamental Business Insights, a dedicated research group specializing in the global healthcare and medical technology industry. Our analysts continuously monitor advancements in medical technologies, clinical adoption trends, regulatory developments, reimbursement policies, healthcare infrastructure investments, competitive strategies, and evolving patient care requirements to deliver timely and reliable market intelligence. The research is developed using a structured methodology that combines primary discussions with healthcare stakeholders, company financial disclosures, regulatory publications, clinical literature, government healthcare databases, medical associations, and other authoritative secondary sources. Market estimates are validated through multiple research techniques, including top-down and bottom-up analysis, before undergoing an internal quality review to ensure accuracy, consistency, and methodological integrity prior to publication.
Delivery
Published
Available
Support
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook